FeesSafety
Pluang+

Phathom reports $84.7M Q3 revenue, $0 copay for VOQUEZNA, and reaffirms 2026 revenue guidance.

Company Fundamentals
18 Nov 2026, 22:45 WIB
The Motley Fool
View Source
Bullish
Phathom reports $84.7M Q3 revenue, $0 copay for VOQUEZNA, and reaffirms 2026 revenue guidance.

Phathom Pharmaceuticals reported third-quarter net revenues of $84.7 million, driven by strong sales of VOQUEZNA, its GERD treatment. The company introduced a $0 copay option through BlinkRx for commercially insured patients to boost prescriptions and fulfillment rates. Phathom achieved operating profitability and positive cash flow for two consecutive quarters, ending Q3 with $184.6 million in cash. Management reaffirmed its full-year 2026 revenue guidance of $310 million to $325 million and is actively defending VOQUEZNA's market exclusivity in federal court against generic drug challenges.

Phathom Pharmaceuticals reported $84.7 million in third-quarter net revenues, highlighting its recent financial performance. For readers following the health sector, here is Pluang's market snapshot as of Nov 19, 2026 02:21 WIB: out of 150 priced health-sector US stocks, 71 rose and 78 fell. Notable movers include IBRX at USD 6.66 (+6.39%), ALMS at USD 4.55 (-5.99%), and SYRE at USD 99.43 (+5.99%).

More News

Alpha Tau Medical reports positive trial results ahead of earnings on Nov 19, 2026.

Alpha Tau Medical reports positive trial results ahead of earnings on Nov 19, 2026.

Alpha Tau Medical is set to report earnings on November 19, 2026, with expected losses of $0.15 per share and revenue of $125,000. The company announced positive clinical trial results from its U.S. REGAIN trial for Alpha DaRT therapy in glioblastoma...

Company Fundamentals
Bullish
54 minutes ago
Nvidia shares fall 2.9% despite strong earnings and raised revenue forecast amid leadership and regulatory concerns.

Nvidia shares fall 2.9% despite strong earnings and raised revenue forecast amid leadership and regulatory concerns.

Nvidia's stock dropped 2.9% to $150.96 after initially rising on strong quarterly results and a raised revenue forecast for fiscal 2028, projecting 75% annual growth. However, investor concerns about leadership uncertainty, including calls for former...

Neutral
1 hour ago
B&G Foods raises full-year sales and EBITDA guidance on strong volume growth and debt reduction plans

B&G Foods raises full-year sales and EBITDA guidance on strong volume growth and debt reduction plans

B&G Foods increased its full-year net sales and adjusted EBITDA guidance following a 5% volume-driven sales growth in Q3 2026. The company is expanding beyond traditional retail into food service, clubs, and private labels to utilize factory capacity...

Company Fundamentals
Bullish
1 hour ago
CoreWeave shares drop 4.13% amid strong AI demand but investor worries over debt and financing costs.

CoreWeave shares drop 4.13% amid strong AI demand but investor worries over debt and financing costs.

CoreWeave's stock fell 4.13% despite strong AI demand and Nvidia's solid earnings, as investors focus on the company's heavy debt and financing challenges. The company reported 168% revenue growth and raised its 2026 revenue forecast to $13-$13.3 bil...

Bearish
1 hour ago
Performance Food Group posts 5.5% sales growth, targets $125M procurement savings by 2028

Performance Food Group posts 5.5% sales growth, targets $125M procurement savings by 2028

Performance Food Group reported a 5.5% net sales increase in fiscal Q1 2027, driven by growth in independent restaurant orders and expanding gross profit margins. The company aims to achieve $125 million in annual procurement savings by fiscal 2028 t...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App